Literature DB >> 25086076

Predictors for mortality in patients with antineutrophil cytoplasmic autoantibody-associated vasculitis: a study of 398 Chinese patients.

Qing-Ying Lai1, Tian-Tian Ma1, Zhi-Ying Li1, Dong-Yuan Chang1, Ming-Hui Zhao1, Min Chen2.   

Abstract

OBJECTIVE: Patients with antineutrophil cytoplasmic autoantibody (ANCA)-associated vasculitis (AAV) have high mortality despite the introduction of immunosuppressive therapy. We investigated factors associated with mortality of patients with AAV in a single Chinese cohort.
METHODS: A total of 398 consecutive patients with AAV diagnosed in our center were recruited. Clinical and laboratory data were collected retrospectively. The predictive values of variables associated with mortality were analyzed.
RESULTS: During followup of a median duration 25.5 months (range 1-196 mo), 135 out of 398 patients (33.9%) died, with 83 deaths within the first 12 months after diagnosis. Independent predictors of all-cause mortality were age (p < 0.001), secondary infection (p < 0.001), pulmonary involvement of AAV (p = 0.012), and initial renal function (p = 0.001). Secondary infection was the leading cause of death (53/153, 39.3%) during the first year after diagnosis, while cardiovascular event was the leading cause of death (15/53, 28.8%) after 12 months from diagnosis. Independent predictors of secondary infection were age (p = 0.002), initial renal function (p = 0.041), lymphocyte counts in the peripheral blood (p = 0.03), and underlying pulmonary involvement of AAV (p = 0.001).
CONCLUSION: Secondary infection is the overall leading cause and independent predictor of death in patients diagnosed with AAV. Cardiovascular event is a major cause of death during the late followup. Prudent monitoring should be given to patients of advancing age with renal dysfunction to reduce adverse events, especially infectious complications.

Entities:  

Keywords:  ANTINEUTROPHIL CYTOPLASMIC AUTOANTIBODY; MORTALITY; PREDICTORS; SECONDARY INFECTION; VASCULITIS

Mesh:

Substances:

Year:  2014        PMID: 25086076     DOI: 10.3899/jrheum.131426

Source DB:  PubMed          Journal:  J Rheumatol        ISSN: 0315-162X            Impact factor:   4.666


  18 in total

Review 1.  Anti-neutrophil cytoplasmic antibody-associated vasculitis: prevalence, treatment, and outcomes.

Authors:  Lei Shi
Journal:  Rheumatol Int       Date:  2017-09-27       Impact factor: 2.631

Review 2.  The Prevalence and Management of Anti-Neutrophil Cytoplasmic Antibody-Associated Vasculitis in China.

Authors:  Zhi-Ying Li; Tian-Tian Ma; Min Chen; Ming-Hui Zhao
Journal:  Kidney Dis (Basel)       Date:  2015-12-09

3.  Adverse events and infectious burden, microbes and temporal outline from immunosuppressive therapy in antineutrophil cytoplasmic antibody-associated vasculitis with native renal function.

Authors:  JulieAnne G McGregor; Roberto Negrete-Lopez; Caroline J Poulton; Jason M Kidd; Suzanne L Katsanos; Lindsey Goetz; Yichun Hu; Patrick H Nachman; Ronald J Falk; Susan L Hogan
Journal:  Nephrol Dial Transplant       Date:  2015-04       Impact factor: 5.992

4.  Reasons for hospitalization and in-hospital mortality for anti-neutrophil cytoplasmic antibody vasculitides: analysis of the National Inpatient Sample.

Authors:  Mavi Rivera; A Villafranca; P Khamooshi; V Reyes; J Sanchez; A Manadan
Journal:  Clin Rheumatol       Date:  2021-08-28       Impact factor: 2.980

5.  Predictors of poor prognosis in ANCA-associated vasculitis (AAV): a single-center prospective study of inpatients in China.

Authors:  Ronglin Gao; Zhenzhen Wu; Xianghuai Xu; Jincheng Pu; Shengnan Pan; Youwei Zhang; Shuqi Zhuang; Lufei Yang; Yuanyuan Liang; Jiamin Song; Jianping Tang; Xuan Wang
Journal:  Clin Exp Med       Date:  2022-10-16       Impact factor: 5.057

6.  Infectious profile in inpatients with ANCA-associated vasculitis: a single-center retrospective study from Southern China.

Authors:  Minxi Lao; Mingcheng Huang; Chen Li; Hao Li; Qian Qiu; Zhongping Zhan; Dongying Chen
Journal:  Clin Rheumatol       Date:  2019-10-02       Impact factor: 2.980

Review 7.  Cutaneous Drug Reactions in the Elderly.

Authors:  James W S Young; Neil H Shear
Journal:  Drugs Aging       Date:  2017-09       Impact factor: 4.271

8.  Severe Infections following Rituximab Treatment in Antineutrophil Cytoplasmic Antibody-Associated Vasculitis.

Authors:  Zhi-Ying Li; Min Chen; Ming-Hui Zhao
Journal:  Kidney Dis (Basel)       Date:  2020-08-23

9.  Impact of Cardiovascular Risk Factors on the Occurrence of Cardiovascular Events in Antineutrophil Cytoplasmic Antibody (ANCA)-Associated Vasculitides.

Authors:  Camille Roubille; Soledad Henriquez; Cédric Mercuzot; Claire Duflos; Bertrand Dunogue; Karine Briot; Loic Guillevin; Benjamin Terrier; Pierre Fesler
Journal:  J Clin Med       Date:  2021-05-25       Impact factor: 4.241

10.  Cutaneous Manifestations of Granulomatosis with Polyangiitis: A Case Series Study.

Authors:  Trinidad Montero-Vilchez; Antonio Martinez-Lopez; Luis Salvador-Rodriguez; Maria Del Carmen Ramírez-Barberena; Jesus Tercedor-Sanchez; Alejandro Molina-Leyva; Salvador Arias-Santiago
Journal:  Acta Derm Venereol       Date:  2020-05-28       Impact factor: 3.875

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.